Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 7:40 PM
Ignite Modification Date:
2025-12-24 @ 7:40 PM
NCT ID:
NCT04690803
Eligibility Criteria:
Inclusion Criteria:
* The subject is a male or female of skin type I to IV between 25 and 75 years of age.
* The subject has mild venous disease (CEAP Class C1) (CLINICAL SEVERITY ETIOLOGY OR CAUSE ANATOMY AND PATHOPHYSIOLOGY)
* Reticular veins and telangiectasias on symmetrical bilateral lower extremities.
* The subject is willing to follow study instructions and complete all required visits, as well as has agreed to and signed the written informed consent form.
* The subject is healthy as judged by medical history and investigator's assessment of current health.
* The subject is not suffering from any skin condition (infection, dermatosis, etc.) that in the opinion of the investigator may place them at risk.
* Females of childbearing potential must use one of the following types of birth control for the duration of the study. These include: Oral contraceptives, contraceptive patches/rings/implants, Implanon®, Depo-Provera®, double-barrier methods (e.g. condoms with spermicide), abstinence, or partner vasectomy, with a documented second acceptable method of birth control should they become sexually active. All birth control measures must be in consistent use for at least 30 days prior to the start of study.
Exclusion Criteria:
* A subject requires greater than 10 mL total of glycerin, including a maximum of 6 mL of polidocanol for foam sclerotherapy, for either lower extremity during a single leg treatment.
* Asymmetric amount, distribution, and/or severity of reticular veins and/or telangiectasias between lower extremities
* The subject has a CEAP Class of C2 or greater, as evidenced by clinically apparent varicosities, venous stasis, stasis dermatitis, lipodermatosclerosis, and/or venous ulceration (or history of lower leg ulcerations).
* The subject has history of or current great saphenous vein (GSV), saphenofemoral junction (SFJ), or saphenopopliteal junction (SPJ) incompetency based on prior Doppler and/or duplex evaluation or has physical exam findings suspicious for it.
* The subject has a history of deep vein thrombosis, thrombophlebitis, thromboembolic disease, and/or underlying hypercoagulable medical condition (e.g. hemophilia, Factor V deficiency).
* The subject has a history of uncontrolled or severe asthma, or asthma requiring hospitalization or intubation.
* The subject has a history of allergic reactions to sclerosing agent.
* The subject has a history of allergic reaction or sensitivity to lidocaine or epinephrine.
* Any of the following medications, procedures or treatments to the purposed treatment area/s
1. Within 6 months prior to screening visit (i.) The subject has undergone sclerotherapy
2. Within 3 months prior to screening visit (I.) NO OTHER COSMETIC OR SURGICAL TREATMENTS TO THE PURPOSED TREATMENT AREA/S
* The subject is non-ambulatory or poorly ambulatory.
* The subject has a history of neurological conditions.
* The subject is pregnant, lactating, or in child bearing age (and sexually active) and not using an approved contraceptive measure.
* The subject is taking disulfiram, tamoxifen, or oral hormone therapy (not including hormonal birth control).
* The subject has a history of noncompliance with clinical protocols.
* The subject has participated in any other clinical trial that involves an investigational medication or device within the last 30 days.
* Planning to have any treatments or procedures to bilateral lower extremities for the duration of the trial.
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
25 Years
Maximum Age:
75 Years
Study:
NCT04690803
Study Brief:
Protocol Section:
NCT04690803